Chimerix Stock

Chimerix Cash Conversion Cycle

Delisted·Apr 17, 2025

The Cash Conversion Cycle (CCC) of Chimerix (CMRX) as of Aug 26, 2026 is 98.14. In the previous year, Cash Conversion Cycle (CCC) was -1.04 M — a change of -100.01% (higher).

Cash Conversion Cycle

98.14

YoY

-100.01%

Last updated:

Cash Conversion Cycle (CCC) of Chimerix is 2026 98.14 . Cash Conversion Cycle (CCC) of Chimerix was 2025 -1.04 M . It decreases by -100.01% higher compared to the previous year.

The Chimerix Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2017
109.93 USD
Jan 1, 2018
-15.82 USD
Jan 1, 2019
12.25 USD
Jan 1, 2020
7.46 USD
Jan 1, 2021
-21.84 USD
Jan 1, 2022
-2,466.64 USD
Jan 1, 2023
-1.04 M USD
Jan 1, 2024
98.14 USD
The Chimerix Cash Conversion Cycle history
YEARCash Conversion CycleYoY
98.14-100.01%
-1.04 M+42,087.43%
-2,466.64+11,195.36%
-21.84-392.79%
7.46-39.10%
12.25-177.41%
-15.82-114.39%
109.93+40.56%
78.21+84.75%
42.33-209.31%
-38.73
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

Cash Conversion Cycle (CCC) of Chimerix is 98.14 in 2026.

Cash Conversion Cycle (CCC) of Chimerix changed from -1.04 M to 98.14, representing a -100.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Chimerix since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Chimerix

All Key Metrics — Chimerix